Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Importation Can Be Triggered By 'Excessive' Price Increases; Now US FDA Has To Decide What That Means

Executive Summary

Did FDA Commissioner Scott Gottlieb and HHS Secretary Alex Azar have a change of heart on importation? Or are they being pressured from above?


Related Content

How A Rapid, Well-Messaged US FDA Offense Is Driving Spectators To Their Feet And Twitter Accounts
How a Rapid and Well-Messaged US FDA Offense Is Driving Spectators to Their Feet and Twitter Accounts
States Take Center Stage In Tackling Rx Drug Pricing
Importation To Address Drug Pricing? Just Do It – But Don’t Justify It
Trump's Drug Pricing Blueprint: An Administrative Vs. Legislative Breakdown
Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan
Trump Praises FDA, But May Leave Firms Queasy With Pricing, Right-To-Try Comments
Drug Pricing Legislation Appears Nowhere In Sight Following Senate Hearing
Right-To-Try Legislation Must Change Language To Narrow Spectrum Of Patients, Gottlieb Says
FDA Can Help On Drug Prices – Except When It Can't, Califf Says


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts